scispace - formally typeset
Journal ArticleDOI

Sleep-disordered breathing in patients with symptomatic heart failure: a contemporary study of prevalence in and characteristics of 700 patients.

Reads0
Chats0
TLDR
Evaluation of the prevalence and nature of sleep‐disordered breathing in patients with symptomatic chronic heart failure receiving therapy according to current guidelines finds that SDB is more common in women than in men.
Abstract
Aim: Evaluation of the prevalence and nature of sleep-disordered breathing (SDB) in patients with symptomatic chronic heart failure (CHF) receiving therapy according to current guidelines. Methods and results: We prospectively screened 700 patients with CHF (NYHA class ≥II, LV-EF ≤40%) for SDB using cardiorespiratory polygraphy (Embletta™). Furthermore, echocardiography, cardiopulmonary exercise and 6-min walk testing were performed. Medication included ACE-inhibitors and/or AT1-receptor blockers in at least 94%, diuretics in 87%, β-blockers in 85%, digitalis in 61% and spironolactone in 62% of patients. SDB was present in 76% of patients (40% central (CSA), 36% obstructive sleep apnoea (OSA)). CSA patients were more symptomatic (NYHA class 2.9±0.5 vs. no SDB 2.57±0.5 or OSA 2.57±0.5; pb0.05) and had a lower LV-EF (27.4±6.6% vs. 29.3±2.6%, pb0.05) than OSA patients. Oxygen uptake (VO2) was lowest in CSA patients: predicted peak VO2 57±16% vs. 64±18% in OSA and 63±17% in no SDB, pb0.05. 6-min walking distances were 331±111 m in CSA, 373±108 m in OSA and 377±118 m in no SDB (pb0.05). Conclusions: This study confirms the high prevalence of SDB, particularly CSA in CHF patients. CSA seems to be a marker of heart failure severity.

read more

Citations
More filters
Journal ArticleDOI

Pathophysiology of Sleep Apnea

TL;DR: This work reviews three types of major long-term sequelae to severe OSA and discusses future research into understanding the pathophysiology of sleep apnea as a basis for uncovering newer forms of treatment of both the ventilatory disorder and its multiple sequelae.
Journal ArticleDOI

Sleep Apnea and Cardiovascular Disease

TL;DR: The American Heart Association/American College of Cardiology Scientific Statement on Sleep Apnea and Cardiovascular Disease as discussed by the authors highlights concepts and evidence important to understanding the interactions between sleep apnea and cardiovascular disease, with particular attention to more recent advances in patient-oriented research.
Journal ArticleDOI

Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure

TL;DR: Adaptive servo-ventilation had no significant effect on the primary end point in patients who had heart failure with reduced ejection fraction and predominantly central sleep apnea, but all-cause and cardiovascular mortality were both increased with this therapy.
Journal ArticleDOI

Epidemiology of Obstructive Sleep Apnea: a Population-based Perspective.

TL;DR: This review summarizes the recent literature on the epidemiology of adult obstructive sleep apnea from various population-based studies and focuses on the economic healthcare burden of OSA and the importance of recognizing the largely undiagnosed OSA population.
Journal ArticleDOI

JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure ― Digest Version ―

Hiroyuki Tsutsui, +61 more
- 25 Sep 2019 - 
TL;DR: This English language document is a revised digest version of Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure (JCS 2017/JHFS 2017) reported at the Japanese Circulation Society Joint Working Groups performed in 2017.
References
More filters
Journal ArticleDOI

The effect of cardiac resynchronization on morbidity and mortality in heart failure

TL;DR: Cardiac resynchronization has been shown to reduce symptoms and improve left ventricular function in patients with heart failure due to systolic dysfunction and cardiac dyssynchrony.
Journal ArticleDOI

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial

TL;DR: Beta-blocker therapy had benefits for survival in stable heart-failure patients and should not be extrapolated to patients with severe class IV symptoms and recent instability because safety and efficacy has not been established in these patients.
Related Papers (5)